A New Delineation Approach for Oral Cavity, Oropharynx, Larynx and Hypopharynx in IMRT for Head and Neck Cancer

NCT05539144 | Completed

• 1 other identifier: HebeiProvincial
• Study Type: interventional
• Target: 8
• Locations: 1 country
• Sites: 1

Brief Summary

The investigators tries a new method to delineating the oral cavity, oropharynx, larynx and hypopharynx, and use the head-and-neck region to test whether the method can to create a good IMRT plan, and alleviate the oral radiation injury, reduce the incidence of adverse reactions.

Conditions

Head and Neck Cancer; Radiotherapy; Oropharynx Abnormality; Radiotherapy; Adverse Effect

Keywords

Oropharynx; Dosimetric parameters; Intensity-modulated radiation treatment（IMRT）; Head and Neck Cancer; Radiotherapy

Outcome Measures

Primary Outcomes (1)

• Dose distribution

  maximum oral cavity, oropharynx, larynx and hypopharynx dose, equivalent uniform dose of the oral cavity, oropharynx, larynx and hypopharynx (EUD), mean oral cavity, oropharynx, larynx and hypopharynx dose, mean organs at risks (OARs) doses, and dose homogeneity inside the target volumes.

  through study completion, an average of 1 year

Study Arms (3)

"Oropharyngeal mucosa" as OARs

EXPERIMENTAL

"Oropharyngeal mucosa" was delineated as OARs and limiting its dose

Radiation: "Oropharyngeal mucosa"

oropharynx as OARs

EXPERIMENTAL

Oropharynx was delineated as OARs and limiting its dose

Radiation: oropharynx

Oropharynx and "oropharyngeal mucosa"as OARs

EXPERIMENTAL

Oropharynx and "oropharyngeal mucosa" was delineated as OARs and limiting its dose

Radiation: oropharynx and "oropharyngeal mucosa"

Interventions

"Oropharyngeal mucosa" RADIATION

"Oropharyngeal mucosa" was delineated as OARs and limiting its dose

"Oropharyngeal mucosa" as OARs

oropharynx RADIATION

oropharynx was delineated as OARs and limiting its dose

oropharynx as OARs

oropharynx and "oropharyngeal mucosa" RADIATION

oropharynx and "oropharyngeal mucosa"were delineated as OARs and limiting its dose

Oropharynx and "oropharyngeal mucosa"as OARs

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• \- patients with previously untreated of the head and neck cancer who received definitive IMRT at our institution

Sponsors & Collaborators

• Hebei Provincial Hospital of Traditional Chinese Medicine: lead

Study Sites (1)

Department of Radiotherapy, Hebei Province Hospital of Chinese Medicine

Shijiazhuang, Hebei, 050011, China

Location

MeSH Terms

Conditions

Head and Neck Neoplasms; Radiation Injuries

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Wounds and Injuries

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: September 5, 2022
• First Posted: September 14, 2022
• Study Start: November 11, 2021
• Primary Completion: December 11, 2022
• Study Completion: December 11, 2023
• Last Updated: May 17, 2024

Record last verified: 2024-05

Locations

CN (1)